Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer

NCT00619996 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Sorafenib (Nexavar)
DRUG: Docetaxel

Sponsor

Italian Trial in Medical Oncology